• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer and Clinical Oncology >Elevated Expression of Hypoxanthine Guanine Phosphoribosyltransferase within Malignant Tissue
【24h】

Elevated Expression of Hypoxanthine Guanine Phosphoribosyltransferase within Malignant Tissue

机译：次黄嘌呤鸟嘌呤磷酸核糖基转移酶在恶性组织中的表达升高

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hypoxanthine Guanine Phosphoribosyltransferase (HPRT) is a housekeeping enzyme involved in the purine synthesis of guanine and inosine in the salvage pathway. While other salvage pathway enzymes, such as TK1, have been established as biomarkers for both cancer cell proliferation and cancer development, little research been done to evaluate whether HPRT has the same potential as a cancer biomarker. We designed this study to determine if HPRT has value as an identifier of malignancy within the most common types of cancer. We utilized histological samples from lung, colon, prostate, and breast cancer with additional normal tissue to evaluate whether there was any elevation of HPRT within malignant samples. In addition, we also assessed general HPRT expression within patient’s samples from The Cancer Genome Atlas (TCGA) to confirm clinical relevance. We found that within a subset of patients, there was significant elevation of HPRT when compared to normal tissue controls. This elevation was seen in 33-55% of the malignant samples and appears to have no dependence on cancer stage. There were slight differences in staining patterns among all the organ types, but overall each organ displayed the same pattern of ‘HPRT high’ and ‘HPRT low’ populations within malignant samples. We found that in our TCGA samples, there was a similar elevation of HPRT that was significant when compared to normal controls. Overall, as an upregulated enzyme that does not directly correlate with stage, HPRT could become a valuable marker in the early diagnosis of a variety of solid tumors.
机译：次黄嘌呤鸟嘌呤磷酸核糖基转移酶（HPRT）是管家酶，参与抢救途径中鸟嘌呤和肌苷的嘌呤合成。虽然其他补救途径酶（例如TK1）已被确立为癌细胞增殖和癌症发展的生物标志物，但很少有研究评估HPRT是否具有与癌症生物标志物相同的潜力。我们设计了这项研究，以确定HPRT在最常见的癌症类型中是否具有作为恶性标识符的价值。我们利用肺癌，结肠癌，前列腺癌和乳腺癌以及其他正常组织的组织学样本来评估恶性样本中HPRT是否升高。此外，我们还评估了癌症基因组图谱（TCGA）患者样本中的一般HPRT表达，以确认临床相关性。我们发现在一部分患者中，与正常组织对照相比，HPRT明显升高。在33-55％的恶性样本中可见到这种升高，并且似乎与癌症分期无关。在所有器官类型中，染色模式均存在细微差异，但总体而言，每个器官在恶性样品中显示的“ HPRT高”和“ HPRT低”种群的模式相同。我们发现，在我们的TCGA样品中，与正常对照相比，HPRT有类似的升高，这是显着的。总体而言，作为一种与阶段不直接相关的上调酶，HPRT可能成为早期诊断各种实体瘤的有价值的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号